166 related articles for article (PubMed ID: 36191979)
1. Prognostic Significance of Clinical Factors Including
Kim JY; Park H; Lee DW; Kim MJ; Shin JE; Lee KE; Lee HN
Anticancer Res; 2022 Oct; 42(10):4945-4954. PubMed ID: 36191979
[TBL] [Abstract][Full Text] [Related]
2. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
Ha HI; Park EY; Eoh KJ; Lee YJ; Seo SS; Kang S; Park SY; Lim MC
Gynecol Oncol; 2022 Feb; 164(2):415-420. PubMed ID: 34924242
[TBL] [Abstract][Full Text] [Related]
4. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
5. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG
Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
[TBL] [Abstract][Full Text] [Related]
7. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
[TBL] [Abstract][Full Text] [Related]
8. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
9. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A
Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259
[TBL] [Abstract][Full Text] [Related]
10. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
11. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
[TBL] [Abstract][Full Text] [Related]
12. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
Yates MS; Meyer LA; Deavers MT; Daniels MS; Keeler ER; Mok SC; Gershenson DM; Lu KH
Cancer Prev Res (Phila); 2011 Mar; 4(3):463-70. PubMed ID: 21278312
[TBL] [Abstract][Full Text] [Related]
13. Disparities between Uptake of Germline
Hur YM; Mun J; Kim MK; Lee M; Kim YH; Kim SC
J Korean Med Sci; 2021 Oct; 36(38):e241. PubMed ID: 34609091
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
15. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
Lacour RA; Westin SN; Meyer LA; Wingo SN; Schorge JO; Brooks R; Mutch D; Molina A; Sutphen R; Barnes M; Elder J; Teoh D; Powell CB; Choubey V; Blank S; Macdonald HR; Brady MF; Urbauer DL; Bodurka D; Gershenson DM; Lu KH
Gynecol Oncol; 2011 May; 121(2):358-63. PubMed ID: 21276604
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
Sakamoto I; Hirotsu Y; Nakagomi H; Ouchi H; Ikegami A; Teramoto K; Amemiya K; Mochizuki H; Omata M
Cancer; 2016 Jan; 122(1):84-90. PubMed ID: 26439132
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants.
Ronchi S; Facchi S; Di Lauro E; Libera L; Carnevali IW; Zefiro F; Alexandrova E; Rizzo F; Sessa F; Tibiletti MG
Pathol Res Pract; 2024 Mar; 255():155183. PubMed ID: 38364651
[TBL] [Abstract][Full Text] [Related]
18. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
19. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]